TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9556142

Group type: EXPERIMENTAL
Intervention: Intravenous olpadronate 4 mg daily for 5 days
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oral olpadronate 200 mg daily after initial intravenous treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intravenous olpadronate only (no oral maintenance)
Number of subjects: 28
Study: 8291961

Group type: EXPERIMENTAL
Intervention: Biofeedback of triceps surae muscle activity during gait
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 0
Study: 2687196

Group type: EXPERIMENTAL
Intervention: ioversol 320
Number of subjects: 60

Group type: COMPARATOR
Intervention: iopamidol-300
Number of subjects: 60
Study: 51964

Group type: EXPERIMENTAL
Intervention: 5-day cyclical combination chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-day cyclical combination chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1-day cyclical combination chemotherapy
Number of subjects: 0
Study: 31744314

Group type: EXPERIMENTAL
Intervention: MobileMums program (MMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (minimal intervention contact)
Number of subjects: 0
Study: 30595477

Group type: EXPERIMENTAL
Intervention: Tocilizumab (IL-6 receptor antibody) during a 12-week intervention with bicycle exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo during a 12-week intervention with bicycle exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tocilizumab (IL-6 receptor antibody) with no exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with no exercise
Number of subjects: 0
Study: 29229110

Group type: EXPERIMENTAL
Intervention: Threshold‐IMT (R‐IMT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Resistive‐IMT (T‐IMT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 25367164

Group type: EXPERIMENTAL
Intervention: Asenapine (ASE)
Number of subjects: 914

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 914
Study: 23433462

Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combitube
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EasyTube
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: I-Gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Endotracheal intubation
Number of subjects: 40
Study: 20945064

Group type: EXPERIMENTAL
Intervention: Tolterodine alone for 10 weeks
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Tolterodine combined with behavioral training for 10 weeks
Number of subjects: 307
Study: 19767148

Group type: EXPERIMENTAL
Intervention: Functional diagnosis presented by a physician with a biomedical orientation
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Functional diagnosis presented by a physician with a biopsychosocial orientation
Number of subjects: 160

Group type: COMPARATOR
Intervention: Organic diagnosis
Number of subjects: 160
Study: 22291076

Group type: EXPERIMENTAL
Intervention: Single high-dose chemotherapy (VIP + 3 cycles of high-dose carboplatin and etoposide)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Sequential high-dose chemotherapy (3 cycles of VIP + 1 cycle of high-dose carboplatin, etoposide, and cyclophosphamide)
Number of subjects: 211
Study: 15034720

Group type: EXPERIMENTAL
Intervention: Placental drainage method
Number of subjects: 958

Group type: COMPARATOR
Intervention: Controlled cord traction method
Number of subjects: 958
Study: 12187294

Group type: EXPERIMENTAL
Intervention: Low cholesterol content formula (< 0.03 g/L)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Medium cholesterol content formula (0.15 g/L)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High cholesterol content formula (0.30 g/L)
Number of subjects: 30

Group type: COMPARATOR
Intervention: All groups (low, medium, high cholesterol)
Number of subjects: 30
Study: 9856918

Group type: EXPERIMENTAL
Intervention: Doxazosin 2 mg for 5 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg for 10 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Doxazosin and Placebo
Number of subjects: 16
Study: 7825521

Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (30 mg Fe daily for 8 weeks)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Twice weekly iron supplementation (30 mg Fe twice per week for 8 weeks)
Number of subjects: 87
Study: 2214868

Group type: EXPERIMENTAL
Intervention: IMREG‐1 (immunosupportive biological agent derived from human leukocytes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 89449

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Computerised tomography, angiography, and scintigraphy
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Combination of ERCP and direct ductal aspiration for cytology
Number of subjects: 73
Study: 31325257

Group type: EXPERIMENTAL
Intervention: Linagliptin (5 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27004945

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 41

Group type: COMPARATOR
Intervention: Miller laryngoscope
Number of subjects: 41
Study: 25552367

Group type: EXPERIMENTAL
Intervention: Combined EpCAM/MCAM CellSearch enrichment
Number of subjects: 68

Group type: COMPARATOR
Intervention: MCAM-positive CTCs
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: EpCAM-positive CTCs and CEC counts
Number of subjects: 68
Study: 23509093

Group type: EXPERIMENTAL
Intervention: 12-week smoking cessation intervention
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Prequit affective trajectories
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Interaction of prequit affective trajectory and abstinence
Number of subjects: 49
Study: 19756024

Group type: EXPERIMENTAL
Intervention: German honey varieties (5 of 8 tested)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: German honey varieties (6 of 8 tested)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glycaemic index and insulinaemic index
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Specific honey varieties
Number of subjects: 10
Study: 18086067

Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 79

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 79
Study: 16877901

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg/day)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 483

Group type: COMPARATOR
Intervention: Venlafaxine XR
Number of subjects: 483
Study: 14520141

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 63

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 63
Study: 10890289

Group type: EXPERIMENTAL
Intervention: Worksite smoking cessation program
Number of subjects: 844
Study: 8888657

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1900483

Group type: COMPARATOR
Intervention: hMG (group A)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist followed by hMG stimulation (group B)
Number of subjects: 302
Study: 6618393

Group type: COMPARATOR
Intervention: Sportgel treatment
Number of subjects: 197
Study: 30224319

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg once daily for 16 weeks
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 158
Study: 27093068

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25243084

Group type: EXPERIMENTAL
Intervention: Implementation intentions intervention
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 98
Study: 21546942

Group type: EXPERIMENTAL
Intervention: Probiotic-supplemented feeding (Lactobacillus rhamnosus GG and Bifidobacterium infantis added to enteral feeding, continued once daily until discharge or 34 weeks PMA)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Probiotic-supplemented feeding
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (unsupplemented feedings)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study: 20423755

Group type: EXPERIMENTAL
Intervention: Oral high-dose dexamethasone
Number of subjects: 62

Group type: COMPARATOR
Intervention: Daily high-dose prednisolone
Number of subjects: 62
Study: 18922117

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by hormonal therapy
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Hormonal therapy alone
Number of subjects: 4500
Study: 15797962

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) and luteinizing hormone releasing hormone analog (LHRHa)
Number of subjects: 14
Study: 12206636

Group type: EXPERIMENTAL
Intervention: Various dose fractionation schedules for breast cancer radiotherapy
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Quality assurance programme for the START Trial
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Adherence to the trial protocol
Number of subjects: 56
Study: 12412823

Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 0.5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 1 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 2.5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 5 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 30
Study: 10214642

Group type: EXPERIMENTAL
Intervention: Repetitions practice group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Random practice group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Combined practice group
Number of subjects: 54
Study: 8594954

Group type: EXPERIMENTAL
Intervention: 0.1 mg fentanyl, sodium thiopental, succinylcholine 1 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.1 mg fentanyl and propofol (demand-adapted)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.2 mg fentanyl and propofol (demand-adapted)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.1 mg fentanyl, propofol, succinylcholine 1 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: sodium thiopental/succinylcholine
Number of subjects: 100
Study: 2538051

Group type: EXPERIMENTAL
Intervention: Wheat rolls with bran labeled with 55Fe and 59Fe
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wheat rolls without bran labeled with 55Fe and 59Fe
Number of subjects: 0
Study: 455774

Group type: EXPERIMENTAL
Intervention: Grommet insertion
Number of subjects: 91

Group type: COMPARATOR
Intervention: Intact ear (control)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both ears (operated and intact)
Number of subjects: 91
Study: 30824401

Group type: EXPERIMENTAL
Intervention: Active yogurt with lipid emulsions encapsulated in calcium-alginate beads
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control yogurt containing nonencapsulated nutrients
Number of subjects: 33
Study: 28182457

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Number of subjects: 171
Study: 26299229

Group type: EXPERIMENTAL
Intervention: Nesiritide treatment
Number of subjects: 4379

Group type: EXPERIMENTAL
Intervention: Diuretic response (weight loss per 40 mg of furosemide)
Number of subjects: 4379

Group type: EXPERIMENTAL
Intervention: Diuretic response (good responders)
Number of subjects: 4379

Group type: EXPERIMENTAL
Intervention: Diuretic response based on urine output per 40 mg of furosemide
Number of subjects: 4379
Study: 23708881

Group type: EXPERIMENTAL
Intervention: Peritonsillar infiltration with dexamethasone and levobupivacaine (Group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: i.v. dexamethasone and peritonsillar levobupivacaine infiltration (Group B)
Number of subjects: 120
Study: 22506436

Group type: EXPERIMENTAL
Intervention: Adjunctive zonisamide
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 20192134

Group type: EXPERIMENTAL
Intervention: Wearing ankle weights
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not wearing ankle weights
Number of subjects: 0
Study: 17911992

Group type: EXPERIMENTAL
Intervention: Retapamulin ointment, 1% (twice daily for 5 days)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Sodium fusidate ointment, 2% (3 times daily for 7 days)
Number of subjects: 519
Study: 15258018

Group type: EXPERIMENTAL
Intervention: Triple procedure with core vitrectomy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (triple procedure without vitrectomy)
Number of subjects: 31
Study: 11502915

Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 9084888

Group type: EXPERIMENTAL
Intervention: Rectal suppository containing ozagrel tablet
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oral ozagrel tablet
Number of subjects: 6
Study: 8125395

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enteral nutritional support in conjunction with radiotherapy or chemotherapy
Number of subjects: 0
Study: 3234516

Group type: EXPERIMENTAL
Intervention: Turbuhaler (multiple dose powder inhaler)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pressurized inhaler
Number of subjects: 12
Study: 29315168

Group type: EXPERIMENTAL
Intervention: Aerobic training regimen of 72 supervised treadmill walking sessions delivered thrice weekly for 24 consecutive weeks
Number of subjects: 25
Study: 26161932

Group type: EXPERIMENTAL
Intervention: Physical function tests (30-s chair stand test)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Dual-task performance (counting backwards)
Number of subjects: 185
Study: 24767299

Group type: EXPERIMENTAL
Intervention: Modified chitosan
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control (no adhesive prevention substance)
Number of subjects: 250
Study: 22375971

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 20070921

Group type: EXPERIMENTAL
Intervention: Same-age peer tutoring (PR)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Cross-age peer tutoring (PR)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control group (no peer tutoring)
Number of subjects: 260
Study: 19114389

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplements and low n-6 PUFA cooking oils and spreads
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control intervention designed to maintain usual fatty acid intake
Number of subjects: 0
Study: 15855365

Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation with collagen cover (ACI-C)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Matrix-induced autologous chondrocyte implantation (MACI)
Number of subjects: 91
Study: 15050086

Group type: EXPERIMENTAL
Intervention: NADA‐Acudetox protocol
Number of subjects: 163

Group type: COMPARATOR
Intervention: Helix control protocol
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Both groups (NADA and Helix)
Number of subjects: 163
Study: 10978947

Group type: EXPERIMENTAL
Intervention: Bismuth-based treatment (colloidal bismuth subcitrate 120 mg qid plus metronidazole 250 mg qid plus tetracycline 500 mg qid)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Bismuth-based treatment
Number of subjects: 111
Study: 8614419

Group type: EXPERIMENTAL
Intervention: Carvedilol (n = 696)
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Placebo (n = 398)
Number of subjects: 1094
Study: 1442450

Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg, 2x/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3925863

Group type: EXPERIMENTAL
Intervention: Perioperative cefoxitin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 3027267

Group type: COMPARATOR
Intervention: ad lib nutritional intake (control group)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: specific nutritional intervention (standard group)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: augmented group
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: nutritional interventions using dietary counselling
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: multivariate prognostic factor analysis for lung cancer
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: multivariate prognostic factor analysis for colorectal cancer
Number of subjects: 192
Study: 31455174

Group type: EXPERIMENTAL
Intervention: L2 immersion program with L1 use prohibited for seven weeks
Number of subjects: 0
Study: 31602573

Group type: EXPERIMENTAL
Intervention: AG200‐15 patch (N=78)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Xulane patch (N=77)
Number of subjects: 83
Study: 28949010

Group type: EXPERIMENTAL
Intervention: 100 mg oral micronized progesterone, six-hourly, starting at 14-18 weeks until 37 weeks or delivery
Number of subjects: 212
Study: 26403840

Group type: EXPERIMENTAL
Intervention: Rights-based sexuality education curriculum
Number of subjects: 1447

Group type: COMPARATOR
Intervention: Basic sex education (control) curriculum
Number of subjects: 1447
Study: 24579221

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 100
Study: 22024310

Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg oral on day 1, 10 mg/day oral on days 2-4) with palonosetron (0.25 mg IV) and dexamethasone (20 mg IV)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Aprepitant (125 mg oral on day 1, 80 mg oral on days 2-3) with palonosetron (0.25 mg IV) and dexamethasone (12 mg IV)
Number of subjects: 241
Study: 18087165

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 16426697

Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg/day
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 11886025

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT), 16 sessions
Number of subjects: 88

Group type: COMPARATOR
Intervention: Usual HMO care
Number of subjects: 88
Study: 9457343

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unresurfaced patella
Number of subjects: 40
Study: 7616988

Group type: EXPERIMENTAL
Intervention: 500 mg zidovudine immediately
Number of subjects: 1637

Group type: EXPERIMENTAL
Intervention: 1500 mg zidovudine immediately
Number of subjects: 1637

Group type: COMPARATOR
Intervention: Deferred therapy (placebo until CD4 < 500)
Number of subjects: 1637
Study: 2092283

Group type: EXPERIMENTAL
Intervention: MivP
Number of subjects: 277

Group type: COMPARATOR
Intervention: VBAMDex
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Ifn‐alpha maintenance
Number of subjects: 277

Group type: COMPARATOR
Intervention: No maintenance treatment
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Stage II patients
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Stage III patients
Number of subjects: 277
Study: 31530662

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (rtCGM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-monitored blood glucose (SMBG)
Number of subjects: 0
Study: 29766772

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg daily)
Number of subjects: 7213

Group type: COMPARATOR
Intervention: Aspirin (100 mg daily)
Number of subjects: 7213
Study: 27445354

Group type: EXPERIMENTAL
Intervention: Communication training for psychiatrists (four group and one individualised session)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Communication training for psychiatrists
Number of subjects: 97
Study: 24987193

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neuromuscular electric stimulation (NMES)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cold water immersion (CWI)
Number of subjects: 30
Study: 22222514

Group type: EXPERIMENTAL
Intervention: Unmet needs for social support
Number of subjects: 83

Group type: COMPARATOR
Intervention: Social support received
Number of subjects: 83
Study: 20823124

Group type: EXPERIMENTAL
Intervention: Day hospital-delivered multifactorial falls prevention programme
Number of subjects: 364

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 364
Study: 18620849

Group type: EXPERIMENTAL
Intervention: 1 mg intra-nasal midazolam
Number of subjects: 65

Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 65
Study: 16828858

Group type: EXPERIMENTAL
Intervention: Four-session one-on-one school nurse-delivered smoking cessation intervention
Number of subjects: 1148
Study: 14765721

Group type: EXPERIMENTAL
Intervention: Bibliotherapy plus telephone contact weight‐loss program
Number of subjects: 43

Group type: COMPARATOR
Intervention: Bibliotherapy weight‐loss program
Number of subjects: 43
Study: 10473085

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicine, and etoposide
Number of subjects: 93

Group type: COMPARATOR
Intervention: Cyclophosphamide, epirubicine and vincristine alternating with carboplatin and etoposide
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 93
Study: 8897751

Group type: EXPERIMENTAL
Intervention: Water fluoridation at 0.7 ppm fluoride using sodium silicofluoride
Number of subjects: 0
Study: 1941407

Group type: EXPERIMENTAL
Intervention: Human milk fortified with human milk protein (HMP)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bovine milk protein preparation (BMP)
Number of subjects: 21